Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 1.00 |
| ▸ | FLT1 | P17948 | 6/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.71 |
| ▸ | ITK | Q08881 | 2/20 | 0.71 |
| ▸ | CDK2 | P24941 | 6/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.66 |
| ▸ | JAK2 | O60674 | 2/20 | 0.66 |
| ▸ | TYK2 | P29597 | 2/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | CLK2 | P49760 | 2/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 2/20 | 0.66 |
| ▸ | CDK1 | P06493 | 2/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.66 |
| ▸ | PLK4 | O00444 | 1/20 | 0.66 |
| ▸ | CHUK | O15111 | 1/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | PAK4 | O96013 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714859 | 1.00 | FGFR1 (1.00) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL3532060 | 0.85 | CHEK1 (0.79) | FGFR1FLT1PDPK1CDK2CHEK1 | |
| SCHEMBL17583341 | 0.85 | FGFR1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL3533024 | 0.85 | PDPK1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL3536504 | 0.85 | FGFR1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL17556295 | 0.85 | FGFR1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL29381764 | 0.85 | FGFR1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL4918041 | 0.84 | PDPK1 (0.76) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL3541234 | 0.84 | ITK (0.71) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL5951751 | 0.84 | PDPK1 (0.80) | FGFR1FLT1PDPK1ITKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-12582781-B2 | Injection systems and methods of their use | MeiraGTx Ocular UK Limited (GB) | 2026-03-24 | — | — | US | disclosed |
| EP-4031214-B1 | INJECTION SYSTEMS | MEIRAGTX OCULAR UK LTD (GB) | 2026-02-18 | — | — | EP | disclosed |
| US-20240197523-A1 | MOTORIZED INJECTION SYSTEM AND METHODS OF USE | MEIRAGTX UK II LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-20220379044-A1 | Injection Systems and Methods of Their Use | MEIRAGTX THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| EP-1442034-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-08-04 | — | — | EP | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035644-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | FGFR1 583/4885FLT1 2074/4885PDPK1 291/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | FGFR1 254/4885FLT1 1117/4885PDPK1 216/4885 |
| US-12582781-B2 | Injection systems and methods of their use | GJA1, MMP1, LNPK | FGFR1 3075/4885FLT1 345/4885PDPK1 4151/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | FGFR1 456/4885FLT1 993/4885PDPK1 3990/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | FGFR1 456/4885FLT1 993/4885PDPK1 3990/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | FGFR1 450/4885FLT1 950/4885PDPK1 4176/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | FGFR1 2175/4885FLT1 3562/4885PDPK1 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.